90877
document
Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia . BACKGROUND Most clinical trials for acute leukemia have reported results after 2-3 years of follow-up . Comparisons between the original data and longer-term follow-up data may be of interest , particularly with regard to promising new therapies . METHODS In 1996 , survival data were updated from three prospective , randomized comparisons of idarubicin and daunorubicin that began in 1984 and 1985 . These were trials of the Memorial Sloan-Kettering Cancer Center ( MSKCC ) , the U.S. Multicenter Study Group , and the Southeastern Cancer Study Group ( SEG ) . The original results of these trials were reported in 1991 and 1992 . RESULTS The original results of the SEG trial demonstrated no significant difference between idarubicin and daunorubicin . The updated survival analysis showed similar results . The MSKCC trial revealed a significant advantage of idarubicin compared with daunorubicin in both the original and the updated analyses . The U.S. Multicenter trial found a significant difference favoring idarubicin in the original analysis , but the difference was not significant in the updated analysis . CONCLUSIONS It is essential that the median length of follow-up be clearly stated in any clinical trial . When the results obtained with a particularly promising new drug or procedure are presented early in the course of study ( within 1-2 years ) , the investigators should strongly consider a repeat evaluation after an additional 3-5 years of follow-up .
90878
Intervention_Pharmacological
idarubicin
90879
Intervention_Pharmacological
daunorubicin
90880
Intervention_Pharmacological
idarubicin and daunorubicin
90881
Outcome_Other
significant difference between idarubicin and daunorubicin .
90882
Outcome_Mortality
survival analysis
90883
Outcome_Other
advantage of idarubicin
90884
Participant_Condition
untreated acute myeloid leukemia .
90885
Participant_Condition
In 1996 , survival data were updated from three prospective , randomized comparisons of idarubicin and daunorubicin that began in 1984 and 1985 . These were trials of the Memorial Sloan-Kettering Cancer Center ( MSKCC ) , the U.S. Multicenter Study Group , and the Southeastern Cancer Study Group ( SEG )